AstraZeneca BRILINTA 90mg Samples May Contain Wrong Tablets
AstraZeneca recalls 8-count BRILINTA 90mg professional sample bottles due to customer reports of containing ZURAMPIC tablets. Affected samples were manufactured for specific lots.
Lower-risk recall
Presence of Foriegn Tablets/Capsules: customer complaint that an 8-count professional sample bottle labeled as BRILINTA 90 mg tablets contained 5 ZURAMPIC 200 mg tablets, in addition to the expected 8 BRILINTA tablets.
Contact the company
What happened, in plain English
AstraZeneca is recalling 8-count BRILINTA 90mg professional sample bottles because some contain ZURAMPIC 200mg tablets instead of the expected BRILINTA tablets. This mix-up could cause incorrect medication use if taken. Read more at govinfonow.com/recall/41596-astrazeneca-brilinta-90mg-samples-may-contain-wrong-tablets.
Source Summary by GovInfoNow · govinfonow.com/recall/41596-astrazeneca-brilinta-90mg-samples-may-contain-wrong-tablets · Updated October 8, 2026 · FDA enforcement record: FDA #D-0958-2017
Cite this page
“AstraZeneca BRILINTA 90mg Samples May Contain Wrong Tablets.” GovInfoNow, updated October 8, 2026. https://govinfonow.com/recall/41596-astrazeneca-brilinta-90mg-samples-may-contain-wrong-tablets. Based on FDA recall #D-0958-2017 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0958-2017%22&limit=1).
Why it’s dangerous
The samples were found to contain 5 ZURAMPIC 200mg tablets instead of the expected 8 BRILINTA tablets. This means patients might take the wrong medication, which could cause incorrect treatment effects.
Who’s affected
Prescription holders of the 8-count BRILINTA 90mg professional sample bottles. Patients who take these samples as medication are at risk of taking the wrong drug.
How to tell if you have this one
Look for 8-count BRILINTA 90mg professional sample bottles with the manufacturer label 'AstraZeneca Pharmaceuticals LP'. The specific lot number JB5047 (expires 10/19) is also listed on the bottle.
- Brand
AstraZeneca- Category
Drug
What to do — step by step
Check Your Samples
Verify if your bottle contains 8 BRILINTA tablets or has extra ZURAMPIC tablets.
Where it went and when
Where it was distributed
Distributed nationwide.
FDA distribution: “Nationwide in the USA and Puerto Rico to physician offices.” States read from FDA’s own wording; “not listed” means the notice does not name it.
Distributed nationwide.
Recall timeline
FDA terminated this recall 11 months after the firm started it.
- Firm started the recall
- FDA classified it Class I
- Published in FDA’s Enforcement Report
- FDA terminated the recall
Dates from the agency record only; steps without a date are left out.
Questions people ask
Is this a serious safety risk?
The recall indicates a mix-up of tablets, but the record does not describe a risk of serious injury. This is considered low risk.
Similar recalls
Latest drug recalls
Keep exploring
Where this comes from
The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.
- Official source: FDA Recall #D-0958-2017 (May 25, 2017) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-0958-2017 to see it in context.
- Plain-language summary written by qwen3:4b on October 8, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
- GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.